Asset Management One Co. Ltd. lowered its holdings in Organon & Co. (NYSE:OGN – Get Rating) by 32.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,340 shares of the company's stock after selling 655 shares during the period. Asset Management One Co. Ltd.'s holdings in Organon & Co. were worth $45,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. MCF Advisors LLC bought a new position in Organon & Co. during the 1st quarter worth approximately $29,000. Column Capital Advisors LLC lifted its holdings in Organon & Co. by 112.0% during the 1st quarter. Column Capital Advisors LLC now owns 850 shares of the company's stock worth $30,000 after buying an additional 449 shares during the last quarter. SouthState Corp lifted its holdings in Organon & Co. by 85.6% during the 1st quarter. SouthState Corp now owns 891 shares of the company's stock worth $31,000 after buying an additional 411 shares during the last quarter. ACG Wealth bought a new position in Organon & Co. during the 2nd quarter worth approximately $31,000. Finally, IndexIQ Advisors LLC bought a new position in Organon & Co. during the 1st quarter worth approximately $35,000. Hedge funds and other institutional investors own 76.28% of the company's stock.

Organon & Co. Price Performance

OGN opened at $23.44 on Monday. Organon & Co. has a 12 month low of $22.88 and a 12 month high of $39.47. The stock has a market cap of $5.96 billion, a P/E ratio of 5.40 and a beta of 0.79. The stock's 50 day moving average price is $27.10 and its 200 day moving average price is $31.64.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 15th. Investors of record on Monday, August 15th were given a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 4.78%. The ex-dividend date of this dividend was Friday, August 12th. Organon & Co.'s dividend payout ratio is currently 25.81%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Morgan Stanley reduced their target price on Organon & Co. from $35.00 to $27.00 and set an "equal weight" rating on the stock in a report on Wednesday, October 12th. Piper Sandler upgraded Organon & Co. from a "neutral" rating to an "overweight" rating and dropped their price target for the stock from $37.00 to $34.00 in a research report on Tuesday, September 6th. Finally, Bank of America cut Organon & Co. from a "neutral" rating to an "underperform" rating and set a $25.00 price target on the stock. in a research report on Friday, October 14th.

Organon & Co. Company Profile

(Get Rating)

Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.

Further Reading

• Get a free copy of the StockNews.com research report on Organon & Co. (OGN)
• Time to Hit Up Hasbro Stock for the Holiday Season
• Should Proctor and Gamble be a Staple in Your Portfolio?
• 3 Fundamentally Sound Mid-Caps to Keep on the Watch List
• Leveraged ETFs, A Bad Investment But Great for Trading
• Should Investors Raise a Glass to Boston Beer Company?

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.